Annexes to COM(2024)274 - - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
dossier | COM(2024)274 - . |
---|---|
document | COM(2024)274 |
date | July 4, 2024 |
14()As an example, Estonia already developed a national alert system.
15() Outside of the scope of this report on falsified medicinal products, manufacturers and marketing authorisation holders that were consulted promote the transformation of the verification system into a ‘track and trace system’. Some NCAs support this idea in the hope that such a system could serve to monitor, prevent and mitigate shortages of medicines. The information that is currently generated by the system does not provide an overview of stocks and volumes of medicinal products, and it does not provide the location of the medicinal packs. The system was not designed with that purpose. Interoperability with other systems outside the scope of the Falsified Medicines Directive and its Delegated Regulation could be analysed as need be.
EN EN